The Swedish government support a R&D project with focus on BMB’s Bonevolent® technology. The funded project comprises 4 partners: KTH Royal Institute of Technology, South Stockholm General Hospital, RISE Research institutes of Sweden and Biomedical Bonding. 

Michael Malkoch, CEO of BMB explains further details: this funding will allow us to develop and properly assess our tissue-friendly implant technology, both from safety and performance aspect. The project will end in early 2022 and by then we should have the commercialization prospective ready for launch.

Note source:

Swelife – For a competitive life science ecosystem in Sweden

Swelife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s partners. We support collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.

www.swelife.se

Medtech4Health is pushing for more medtech ideas and solutions to be implemented and be beneficial. Working together with healthcare, academia and the business world, we create value for patients and a strengthened medical technology industry. Medtech4Health is funded by the government through Sweden's innovation agency Vinnova.

www.medtech4health.se